Compare HURC & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HURC | MXCT |
|---|---|---|
| Founded | 1968 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.6M | 129.6M |
| IPO Year | 1995 | 2021 |
| Metric | HURC | MXCT |
|---|---|---|
| Price | $21.50 | $1.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 25.3K | ★ 1.0M |
| Earning Date | 06-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $178,554,000.00 | $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.50 | $0.64 |
| 52 Week High | $22.50 | $2.37 |
| Indicator | HURC | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 80.65 | 56.16 |
| Support Level | $16.55 | $0.77 |
| Resistance Level | N/A | $1.16 |
| Average True Range (ATR) | 0.71 | 0.09 |
| MACD | 0.48 | -0.01 |
| Stochastic Oscillator | 85.33 | 52.31 |
Hurco Companies Inc is an international industrial technology company that designs, manufactures, and sells computerized (CNC) machine tools for the metal cutting industry through a international sales and distribution network. Its proprietary control systems and software are sold as integral components of its machine tools. The Company also provides machine tool components, automation solutions, software options, upgrades, accessories, replacement parts, and related support services. It operates in the Americas, Europe, and Asia Pacific, with the Americas contributing the majority of revenue. Its core products include vertical and horizontal machining centers (mills), turning centers (lathes), and toolroom machines.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.